ReviewJournal of infection in developing countries2011
Developing live vaccines against plague.
Review in Journal of infection in developing countries, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Live Plague Vaccine Development: Past, Present, and Future.Vaccines · 2025Review
- Force spectroscopy of interactions between Yersinia pseudotuberculosis and Yersinia pestis cells and monoclonal antibodies using optical tweezers.European biophysics journal : EBJ · 2022Article
- Review
- Plague vaccines: new developments in an ongoing search.Applied microbiology and biotechnology · 2021Review
- Protection Elicited by Attenuated LiveVaccines · 2021Article
- Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to theFrontiers in immunology · 2021Article
- Deliberate release: Plague - A review.Journal of biosafety and biosecurity · 2020Review
- Optimization and One-Step Purification of Recombinant V Antigen Production from Yersinia pestis.Molecular biotechnology · 2020Article
- Construction of a Live-Attenuated Vaccine Strain ofFrontiers in cellular and infection microbiology · 2020Article
- Vaccines for emerging pathogens: prospects for licensure.Clinical and experimental immunology · 2019Review
- Plague vaccine: recent progress and prospects.NPJ vaccines · 2019Review
- A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.Clinical and vaccine immunology : CVI · 2016Article
- Plague Vaccine Development: Current Research and Future Trends.Frontiers in immunology · 2016Review
- Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.Clinical and vaccine immunology : CVI · 2015Article
- LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.Infection and immunity · 2014Article
- Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain.Comparative immunology, microbiology and infectious diseases · 2013Article
- Rational considerations about development of live attenuated Yersinia pestis vaccines.Current pharmaceutical biotechnology · 2013Review
- Plague vaccines: current developments and future perspectives.Emerging microbes & infections · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Three great plague pandemics caused by the gram-negative bacterium Yersinia pestis have killed nearly 200 million people and it has been linked to biowarfare in the past. Plague is endemic in many parts of the world. In addition, the risk of plague as a bioweapon has prompted increased research to develop plague vaccines against this disease. Injectable subunit vaccines are being developed in the United States and United Kingdom. However, the live attenuated Y. pestis-EV NIIEG strain has been used as a vaccine for more than 70 years in the former Soviet Union and in some parts of Asia and provides a high degree of efficacy against plague. This vaccine has not gained general acceptance because of safety concerns. In recent years, modern molecular biological techniques have been applied to Y. pestis to construct strains with specific defined mutations designed to create safe, immunogenic vaccines with potential for use in humans and as bait vaccines to reduce the load of Y. pestis in the environment. In addition, a number of live, vectored vaccines have been reported using attenuated viral vectors or attenuated Salmonella strains to deliver plague antigens. Here we summarize the progress of live attenuated vaccines against plagu.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.